DMD and neuromuscular disease caused by qualitative or quantitative defects of dystrophin: In conclusion, this study provides evidence that analysis of gene expression in blood of preclinical and clinical samples of dystrophinopathies can deliver information of pathways affected in skeletal muscle, and it can be employed to show response to dystrophin‐restoring therapy (even after sub‐optimal dystrophin recovery) and to monitor patient performance.